News Archive - Page 4 of 5

Can deconstructing the biological clock help treat diabetes and cancer?

http://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/

Two Peer-Reviewed Studies Focusing on Unique Therapeutic Impact of VeroScience’s Cycloset Recently Published in Journal of Diabetes Research

http://www.prnewswire.com/news-releases/two-peer-reviewed-studies-focusing-on-unique-therapeutic-impact-of-verosciences-cycloset-recently-published-in-journal-of-diabetes-research-300098977.html

VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) and Neurophysiological Investigations of Brain Dopamine Regulation of Metabolism with Eight Papers Presented at the 2015 American Diabetes Association

http://www.prnewswire.com/news-releases/veroscience-continues-clinical-evaluation-of-bromocriptine-qr-cycloset-and-neurophysiological-investigations-of-brain-dopamine-regulation-of-metabolism-with-eight-papers-presented-at-the-2015-american-diabetes-association-confer-300095056.html

Cycloset (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm

Cycloset is recommended for dual therapy for patients with entry HbA1c ≥ 7.5% SAN DIEGO & TIVERTON, R.I. –(BUSINESS WIRE)– Santarus, Inc. […]

Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for Cycloset® (bromocriptine mesylate) for the Management of Type 2 Diabetes

Experts conclude that favorable cardiovascular profile of Cycloset suggests it may be useful in the treatment of patients with type 2 diabetes […]

Santarus and VeroScience Announce Publication of Positive Data from Pivotal Cycloset® (bromocriptine mesylate) Efficacy Study

Cycloset add-on therapy provided significant improvement in glycemic control versus placebo in patients with type 2 diabetes poorly controlled on one or […]

Santarus and VeroScience Announce Publication of New Analysis of Cycloset (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association

In assessing cardiovascular safety in type 2 diabetes subjects, Cycloset demonstrated a significant 52% relative risk reduction in cardiovascular events (composite endpoint […]

Archives: News